CN103501609A - 用于偏头痛的治疗 - Google Patents
用于偏头痛的治疗 Download PDFInfo
- Publication number
- CN103501609A CN103501609A CN201280010586.9A CN201280010586A CN103501609A CN 103501609 A CN103501609 A CN 103501609A CN 201280010586 A CN201280010586 A CN 201280010586A CN 103501609 A CN103501609 A CN 103501609A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical preparation
- active component
- treatment
- nicotine
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019695 Migraine disease Diseases 0.000 title abstract description 11
- 206010027599 migraine Diseases 0.000 title abstract description 10
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 20
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 18
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 18
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 16
- 229960002715 nicotine Drugs 0.000 claims abstract description 16
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 16
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 10
- 229960001948 caffeine Drugs 0.000 claims abstract description 10
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 10
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000007864 aqueous solution Substances 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 22
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 16
- 235000008729 phenylalanine Nutrition 0.000 claims description 9
- 229960005190 phenylalanine Drugs 0.000 claims description 9
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 229940024606 amino acid Drugs 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 235000004400 serine Nutrition 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 229960004799 tryptophan Drugs 0.000 claims description 3
- 229960004441 tyrosine Drugs 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 16
- 230000002460 anti-migrenic effect Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 10
- 235000013361 beverage Nutrition 0.000 description 8
- 238000011160 research Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 208000018316 severe headache Diseases 0.000 description 2
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960002133 almotriptan Drugs 0.000 description 1
- 229950002360 avitriptan Drugs 0.000 description 1
- WRZVGHXUPBWIOO-UHFFFAOYSA-N avitriptan Chemical compound C12=CC(CS(=O)(=O)NC)=CC=C2NC=C1CCCN(CC1)CCN1C1=NC=NC=C1OC WRZVGHXUPBWIOO-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960002284 frovatriptan Drugs 0.000 description 1
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 206010052787 migraine without aura Diseases 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229960000425 rizatriptan Drugs 0.000 description 1
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960001360 zolmitriptan Drugs 0.000 description 1
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161436370P | 2011-01-26 | 2011-01-26 | |
| US61/436,370 | 2011-01-26 | ||
| PCT/US2012/022788 WO2012103377A1 (en) | 2011-01-26 | 2012-01-26 | Remedy for migraine headache |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103501609A true CN103501609A (zh) | 2014-01-08 |
Family
ID=46581171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280010586.9A Pending CN103501609A (zh) | 2011-01-26 | 2012-01-26 | 用于偏头痛的治疗 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8618118B2 (enExample) |
| EP (1) | EP2667711A4 (enExample) |
| JP (1) | JP2014503592A (enExample) |
| CN (1) | CN103501609A (enExample) |
| AU (1) | AU2012211204B2 (enExample) |
| CA (1) | CA2826019C (enExample) |
| EA (1) | EA201370171A1 (enExample) |
| WO (1) | WO2012103377A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106511984A (zh) * | 2016-12-02 | 2017-03-22 | 郑州莉迪亚医药科技有限公司 | 一种用于偏头疼的药物及其制备方法 |
| CN106581045A (zh) * | 2016-12-02 | 2017-04-26 | 郑州莉迪亚医药科技有限公司 | 一种治疗偏头疼的药物及其制备方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101982923B1 (ko) * | 2017-07-05 | 2019-05-27 | 가천대학교 산학협력단 | 편두통 진단용 바이오마커 및 상기 바이오마커를 이용한 편두통 진단방법 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6294520B1 (en) * | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
| US20060105023A1 (en) * | 2001-12-10 | 2006-05-18 | Knight Joseph R | Treatment of neurological disorders with nicotine |
| US20090202635A1 (en) * | 2008-02-08 | 2009-08-13 | Stephen Michael Scott | Delivery System, Application, and Method |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9020A (en) * | 1852-06-15 | Improved machine for peaking sheet-metal tubes | ||
| US2018A (en) * | 1841-03-26 | Joseph francis | ||
| US6010A (en) * | 1849-01-09 | Improvement in the manufacture of hats | ||
| IT1179866B (it) | 1984-12-12 | 1987-09-16 | Rotta Research Lab | Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono |
| US4665069A (en) | 1985-04-02 | 1987-05-12 | Barnett Rosenberg | Analgesic composition and method of relieving pain |
| US4639465A (en) | 1985-08-30 | 1987-01-27 | Commonwealth Medical Corporation Of America | Method and composition for relieving pain |
| SE8701662L (sv) * | 1987-04-22 | 1988-10-23 | Gelder Nico M Van | Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna |
| US5326569A (en) * | 1992-12-23 | 1994-07-05 | Abbott Laboratories | Medical foods for the nutritional support of child/adult metabolic diseases |
| EP0740935A4 (en) * | 1994-02-24 | 1999-06-16 | Otsuka Pharma Co Ltd | ANALGETIC ACTIVITY AMPLIFIER |
| CA2127573A1 (en) * | 1994-07-07 | 1996-01-08 | Angela Christine Gedye | Vasotonic treatment for migraines |
| GB9617990D0 (en) * | 1996-08-29 | 1996-10-09 | Scotia Holdings Plc | Treatment of pain |
| US6268386B1 (en) | 1998-06-25 | 2001-07-31 | Marshall Anlauf Thompson | Nicotine beverage |
| IT1320776B1 (it) | 2000-08-07 | 2003-12-10 | Giampiero Valletta | Composizione farmaceutica a base di un'associazione vitaminica per laterapia delle cefalee primarie |
| CA2479218A1 (en) * | 2002-03-21 | 2003-10-02 | Martin C. Hinz | Serotonin and catecholamine system segment optimization technology |
| ITMI20041689A1 (it) | 2004-09-01 | 2004-12-02 | Bojidar Mihaylov Stankov | Nuove formulazioni di rilascio controllato contenenti 5-idrossitriptofano e triptofano |
| US20070043120A1 (en) | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| US20070286909A1 (en) * | 2006-06-07 | 2007-12-13 | Daniel S. Smith | Amino acid compositions |
| US20080139510A1 (en) | 2006-12-07 | 2008-06-12 | Abe Rose | Treatment of migraine headaches with sublingual amino acids |
| GB2450076B (en) * | 2007-05-17 | 2012-09-26 | Sis Science In Sport Ltd | Nutritional composition |
| EP2240022B1 (en) * | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
| WO2010112942A1 (en) | 2009-04-02 | 2010-10-07 | Shire Llc | Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof |
-
2012
- 2012-01-26 EP EP12738959.1A patent/EP2667711A4/en not_active Withdrawn
- 2012-01-26 AU AU2012211204A patent/AU2012211204B2/en not_active Ceased
- 2012-01-26 US US13/359,393 patent/US8618118B2/en not_active Expired - Fee Related
- 2012-01-26 CN CN201280010586.9A patent/CN103501609A/zh active Pending
- 2012-01-26 JP JP2013551347A patent/JP2014503592A/ja active Pending
- 2012-01-26 WO PCT/US2012/022788 patent/WO2012103377A1/en not_active Ceased
- 2012-01-26 EA EA201370171A patent/EA201370171A1/ru unknown
- 2012-01-26 CA CA2826019A patent/CA2826019C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6294520B1 (en) * | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
| US20060105023A1 (en) * | 2001-12-10 | 2006-05-18 | Knight Joseph R | Treatment of neurological disorders with nicotine |
| US20090202635A1 (en) * | 2008-02-08 | 2009-08-13 | Stephen Michael Scott | Delivery System, Application, and Method |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106511984A (zh) * | 2016-12-02 | 2017-03-22 | 郑州莉迪亚医药科技有限公司 | 一种用于偏头疼的药物及其制备方法 |
| CN106581045A (zh) * | 2016-12-02 | 2017-04-26 | 郑州莉迪亚医药科技有限公司 | 一种治疗偏头疼的药物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012103377A1 (en) | 2012-08-02 |
| AU2012211204B2 (en) | 2014-04-24 |
| CA2826019C (en) | 2017-08-01 |
| CA2826019A1 (en) | 2012-08-02 |
| EP2667711A1 (en) | 2013-12-04 |
| US20130143903A1 (en) | 2013-06-06 |
| US8618118B2 (en) | 2013-12-31 |
| AU2012211204A1 (en) | 2013-09-12 |
| EP2667711A4 (en) | 2014-11-12 |
| JP2014503592A (ja) | 2014-02-13 |
| EA201370171A1 (ru) | 2014-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Glassman et al. | Potentiation of a monoamine oxidase inhibitor by tryptophan | |
| US8420624B2 (en) | Methods for treating or preventing symptoms of hormonal variations | |
| JP2024074963A (ja) | トラジピタントによる治療方法 | |
| JP2016521755A5 (enExample) | ||
| Müller et al. | Effect of butorphanol, midazolam or ketamine on romifidine based sedation in horses during standing cheek tooth removal | |
| EP1631294B1 (en) | A method of treating an anxiety disorder | |
| JP2020500915A (ja) | 末梢神経障害性疼痛の治療に使用するための局所作用用フェニトイン | |
| WO2023137094A1 (en) | Psilocin benzoate formulation for intravenous infusion | |
| CN106666746B (zh) | 具有调节神经递质平衡功能的芦笋组合物及其制备方法、芦笋组合物粉剂 | |
| CA2770211A1 (en) | Methods for iontophoretically treating nausea and migraine | |
| CN103501609A (zh) | 用于偏头痛的治疗 | |
| JP2015516974A5 (ja) | 骨の線維柱帯における空洞病巣発生を有する正常又は増加した骨組織石灰化に伴う非定型骨粗鬆症を対象にする予防または治療剤 | |
| US20140147519A1 (en) | Migraine Treatment | |
| Sandyk | A drug naive parkinsonian patient successfully treated with weak electromagnetic fields | |
| CN117715633A (zh) | 用于治疗covid-19、自身免疫性疾病或细胞因子风暴反应的利多卡因或阿替卡因 | |
| JP2024529777A (ja) | ＡＲＮｉとカルシウムイオンアンタゴニストとの医薬組成物および応用 | |
| JP2005162745A (ja) | 高血圧改善剤 | |
| Kumar et al. | Effect of coffee on blood pressure and electrocardiographic changes in young and elderly healthy subjects | |
| Kulkarni et al. | Serotonin | |
| CN111643606B (zh) | 一种用以治疗失眠的凝胶贴膏及其制备方法 | |
| JP2002532549A (ja) | ５ｈｔ３−受容体−アンタゴニストの使用 | |
| Liester et al. | Ketamine: Review and Hypothesis for Potential Use in Spinal Cord Injury | |
| JP6878021B2 (ja) | トリプタンとアスコルビン酸を含有する医薬組成物 | |
| Afzal et al. | An Integrative Review of Chronic Fatigue Syndrome (CFS): Clinical Insights and Therapeutic Approaches in Unani and Modern Medicine. | |
| CN111529489A (zh) | 一种含有地西泮的鼻腔喷雾剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140108 |